We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+15.44%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$855M
AUM Growth
-$19.9M
Cap. Flow
-$111M
Cap. Flow %
-12.98%
Top 10 Hldgs %
29.46%
Holding
101
New
12
Increased
17
Reduced
38
Closed
8

Top Buys

Rank Stock Value
1
LIVN icon
LivaNova
LIVN
+$11.2M
2
ABMD
Abiomed Inc
ABMD
+$9.03M
3
NKTR icon
Nektar Therapeutics
NKTR
+$8.67M
4
EXAS
Exact Sciences
EXAS
+$8.51M
5
MGNX icon
MacroGenics
MGNX
+$7.35M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$18.1M
2
INCY icon
Incyte
INCY
+$13.5M
3
CELG
Celgene Corp
CELG
+$13.1M
4
SAGE
Sage Therapeutics
SAGE
+$12.4M
5
EXEL icon
Exelixis
EXEL
+$12.1M

Sector Composition

Rank Sector Weight
1 Healthcare 93.64%
2 Technology 0.15%
3 Energy 0.14%
4 Financials 0.1%
5 Communication Services 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
26
DELISTED
Aerie Pharmaceuticals
AERI
$12.3M 1.44%
260,000
-20,000
-7% -$880K
IMMU
27
DELISTED
Immunomedics Inc
IMMU
$11.8M 1.38%
616,367
+136,037
+28% +$2.19M
MYOK
28
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$11.7M 1.37%
225,024
+35,702
+19% +$1.64M
ITCI
29
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$11.6M 1.35%
949,833
+289,851
+44% +$3.7M
SGEN
30
DELISTED
Seagen Inc. Common Stock
SGEN
$11M 1.29%
150,598
-91,600
-38% -$6.52M
BMY icon
31
Bristol-Myers Squibb
BMY
$132B
$11M 1.28%
230,000
-140,000
-38% -$6.97M
CNC icon
32
Centene
CNC
$32.5B
$10.6M 1.24%
200,000
-40,000
-17% -$2.43M
ARNA
33
DELISTED
Arena Pharmaceuticals Inc
ARNA
$10.5M 1.23%
234,558
-137,300
-37% -$6.3M
KYNB
34
Kyntra Bio
KYNB
$29.4M
$10.3M 1.2%
7,580
-4,489
-37% -$6.09M
EXEL icon
35
Exelixis
EXEL
$13.4B
$10.2M 1.2%
430,000
-528,994
-55% -$12.1M
XNCR icon
36
Xencor
XNCR
$1.55B
$10.1M 1.18%
325,965
+107,428
+49% +$3.57M
MRTX
37
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$9.32M 1.09%
127,093
+42,093
+50% +$2.86M
COR icon
38
Cencora
COR
$61.2B
$9.27M 1.08%
116,520
+15,000
+15% +$1.21M
WBA
39
DELISTED
Walgreens Boots Alliance
WBA
$9.17M 1.07%
145,000
– –
EXAS
40
DELISTED
Exact Sciences
EXAS
$8.66M 1.01%
+100,000
New +$8.51M
BLUE
41
DELISTED
bluebird bio
BLUE
$8.65M 1.01%
4,246
-4,852
-53% -$8.54M
INCY icon
42
Incyte
INCY
$24.4B
$8.6M 1.01%
100,000
-166,416
-62% -$13.5M
AGIO icon
43
Agios Pharmaceuticals
AGIO
$1.93B
$8.57M 1%
127,012
– –
ALNY icon
44
Alnylam Pharmaceuticals
ALNY
$29.3B
$8.55M 1%
91,550
-20,000
-18% -$1.67M
IOVA icon
45
Iovance Biotherapeutics
IOVA
$2.87B
$8.37M 0.98%
879,600
-325,895
-27% -$3.17M
SAGE
46
DELISTED
Sage Therapeutics
SAGE
$8.21M 0.96%
51,639
-85,700
-62% -$12.4M
TMO icon
47
Thermo Fisher Scientific
TMO
$220B
$8.21M 0.96%
30,000
– –
OMCL icon
48
Omnicell
OMCL
$1.68B
$8.11M 0.95%
100,375
– –
SGMO
49
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$8.05M 0.94%
843,957
-260,000
-24% -$2.66M
AMRN
50
Amarin Corp
AMRN
$303M
$7.7M 0.9%
18,540
+13,540
+271% +$4.88M
1
2
3 4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2019 Portfolio in Review

As of Q1 2019, Rhenman & Partners Asset Management held 101 positions worth $855M, down 2.3% from $875M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $111M in Q1 2019, closing 8 positions and reducing 38 holdings. Its most notable exit was Biogen, an estimated $18.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 94% a quarter earlier, followed by Technology and Energy.

Against the trend, Rhenman & Partners Asset Management opened a new position in Exact Sciences worth $8.66M.

  • Rhenman & Partners Asset Management's largest Q1 2019 buy was Exact Sciences: 100,000 shares worth $8.66M.
  • Rhenman & Partners Asset Management added most to LivaNova in Q1 2019, an estimated $11.2M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2019 reduction was Incyte, cutting an estimated $13.5M.
  • Rhenman & Partners Asset Management fully exited Biogen in Q1 2019, selling an estimated $18.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $855M portfolio in Q1 2019.
  • Rhenman & Partners Asset Management opened 12 new positions and closed 8 in Q1 2019.
  • Rhenman & Partners Asset Management's portfolio value fell 2.3% quarter-over-quarter to $855M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2019, filed 11 Apr 2019.